Info
Dr. David Spigel addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.
8 anni fa
#adjuvant, #alk, #cancer, #cancergrace, #cannon, #center, #david, #egfr, #grace, #gracecast, #molecular, #mutation, #oncology, #postoperative, #rearrangement, #sarah, #spigel, #targeted, #therapy, #treatment
Scopri di più
Cerca
